Scientists at Takeda come to work every day focused on translating science into highly innovative, life-changing medicines. We are focused on therapies with transformative and curative potential, which is why we’re investing in the power of innate immunity and the promise of cell therapy.
Oncology cell therapy is a type of immunotherapy that uses genetically modified immune cells to find and kill cancer cells. Next-generation cell therapy is one of the multiple investigational platforms that we are researching in oncology as part of our focus on redirected immunity, which involves mobilizing cells of the immune system to directly attack tumors. We are pursuing multiple cell therapy platforms and engineering strategies, including those derived from natural killer (NK) cells, T cells and induced pluripotent stem (iPS) cells, among others. These approaches are intended to build upon the first generation of cell therapies in cancer treatment with the potential to improve safety, efficacy and patient convenience.
Takeda built a state-of-the-art R&D manufacturing facility at our global R&D center in Boston, Massachusetts. Here, scientists can manufacture different types of autologous and allogeneic cell therapies for clinical trials in the U.S., E.U. and Japan.
Because cell therapies are engineered from living cells, they need to be manufactured in a highly regulated environment to maintain cleanliness, consistency and contamination control. Each different cell therapy platform has a unique process and requirements for how they are formulated, manufactured, transported and ultimately administered to patients. Learn more about the cell therapy manufacturing process in the video below.
Autologous vs. Allogeneic Cell Therapies
Learn how the manufacturing processes are different for these two different types of cell therapies.
The development, manufacturing and commercialization of cell therapies is complex, so collaboration across the development lifecycle is critical. Takeda’s Cell Therapy Translational Engine (CTTE) provides bioengineering, chemistry, manufacturing and control (CMC), data management, analytical and clinical and translational capabilities in a single footprint. This collaborative structure encourages continued improvement from research and development through product approval and beyond.
Collaboration with the CTTE, our network of partners and across Takeda is essential to ensuring seamless execution and uncovering insights across our programs that are critical to bringing the next generation of cell therapies to patients who are waiting.